| Autor: |
Vicini, P, Fields, O, Lai, E, Litwack, ED, Martin, A‐M, Morgan, TM, Pacanowski, MA, Papaluca, M, Perez, OD, Ringel, MS, Robson, M, Sakul, H, Vockley, J, Zaks, T, Dolsten, M, Søgaard, M |
| Předmět: |
|
| Zdroj: |
Clinical Pharmacology & Therapeutics; Feb2016, Vol. 99 Issue 2, p198-207, 10p |
| Abstrakt: |
High throughput molecular and functional profiling of patients is a key driver of precision medicine. DNA and RNA characterization has been enabled at unprecedented cost and scale through rapid, disruptive progress in sequencing technology, but challenges persist in data management and interpretation. We analyze the state-of-the-art of large-scale unbiased sequencing in drug discovery and development, including technology, application, ethical, regulatory, policy and commercial considerations, and discuss issues of LUS implementation in clinical and regulatory practice. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text